Compare · MRK vs STTK
MRK vs STTK
Side-by-side comparison of Merck & Company Inc. (MRK) and Shattuck Labs Inc. (STTK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and STTK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $284.45B, about 656.6x STTK ($433.2M).
- Over the past year, MRK is up 51.0% and STTK is up 440.7% - STTK leads by 389.7 points.
- MRK has been more active in the news (15 items in the past 4 weeks vs 9 for STTK).
- MRK has more recent analyst coverage (25 ratings vs 13 for STTK).
- Company
- Merck & Company Inc.
- Shattuck Labs Inc.
- Price
- $115.16-3.01%
- $5.65-4.88%
- Market cap
- $284.45B
- $433.2M
- 1M return
- +5.48%
- -20.76%
- 1Y return
- +50.98%
- +440.67%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 15
- 9
- Recent ratings
- 25
- 13
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Shattuck Labs Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Latest MRK
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
- SEC Form SD filed by Merck & Company Inc.
- FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
- Merck & Company Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care
- Merck to Participate in the Jefferies Global Healthcare Conference
- Merck Announces Third-Quarter 2026 Dividend
- Merck & Company Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Merck & Company Inc.
- Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries
Latest STTK
- Director Siegall Clay B was granted 128,054 shares, increasing direct ownership by 100% to 256,108 units (SEC Form 4)
- Chief Technical Officer Shukla Abhinav A. was granted 5,122 shares, increasing direct ownership by 6% to 86,380 units (SEC Form 4)
- Officer Stout Stephen was granted 12,805 shares, increasing direct ownership by 16% to 93,366 units (SEC Form 4)
- Chief Financial Officer Neill Andrew R was granted 64,027 shares, increasing direct ownership by 28% to 292,251 units (SEC Form 4)
- Chief Technical Officer Shukla Abhinav A. exercised 2,032 shares at a strike of $3.57 and sold $14,244 worth of shares (2,032 units at $7.01) as part of a pre-agreed trading plan (SEC Form 4) to cover taxes
- Chief Medical Officer Pandite Arundathy N. sold $198,300 worth of shares (30,000 units at $6.61) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 166,219 units (SEC Form 4)
- Chief Executive Officer Schreiber Taylor was granted 25,610 shares, increasing direct ownership by 27% to 122,222 units (SEC Form 4)
- Officer Stout Stephen covered exercise/tax liability with 968 shares, decreasing direct ownership by 1% to 80,561 units (SEC Form 4)
- SEC Form 144 filed by Shattuck Labs Inc.
- SEC Form 10-Q filed by Shattuck Labs Inc.